P119 Design of a randomized, open-label trial adding custirsen, a novel clusterin inhibitor, to cabazitaxel/prednisone in second-line treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC): The AFFINITY phase 3 study
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- November 2013
has subject area
- 1103 Clinical Sciences (FoR)
- Urology & Nephrology (Science Metrix)
published in
- European Urology Open Science Journal